SOLUBLE FAS/FASL LEVELS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH INFLIXIMAB AND ADALIMUMAB

被引：0
|
作者：
Terenzi, R. [1 ]
Guiducci, S. [1 ]
Nacci, F. [1 ]
Romano, E. [1 ]
Manetti, M. [1 ]
Peruzzi, F. [1 ]
Bruni, C. [1 ]
Bartoli, F. [1 ]
Matucci-Cerinic, M. [1 ]
机构：
[1] Univ Florence, Dept Med, Div Rheumatol, Florence, Italy
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 71卷
关键词：
D O I：
10.1136/annrheumdis-2012-eular.3097
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：522 / 522
页数：1
相关论文
共 50 条
  • [41] The Monitoring of Infliximab Levels at Early Stages Can Predict the Development of Anti-Infliximab Antibodies in a Cohort of Rheumatoid Arthritis Patients Treated with Infliximab
    Plasencia-Rodriguez, Chamaida
    Pascual-Salcedo, Dora
    Gema Bonilla, Maria
    Villalba, Alejandro
    Peiteado, Diana
    Nuno, Laura
    Aguado, Pilar
    Jurado, Teresa
    Martin-Mola, Emilio
    Balsa, Alejandro
    ARTHRITIS & RHEUMATOLOGY, 2014, 66 : S1098 - S1098
  • [42] Health economic evaluation of patients with rheumatoid arthritis (RA) treated with adalimumab
    Vanoverbeke, N
    Annemans, L
    Cauchie, P
    Hendrickx, E
    VALUE IN HEALTH, 2004, 7 (06) : 663 - 663
  • [43] Relation of the Fas and FasL gene polymorphisms with susceptibility to and severity of rheumatoid arthritis
    Yildir, Seyfi
    Sezgin, Melek
    Barlas, Ibrahim Omer
    Turkoz, Gozde
    Ankarali, Handan Camdeviren
    Sahin, Gunsah
    Erdal, Mehmet Emin
    RHEUMATOLOGY INTERNATIONAL, 2013, 33 (10) : 2637 - 2645
  • [44] Incidence of Anti-Drug Antibodies in Rheumatoid Arthritis Patients Treated with Adalimumab, Etanercept, or Infliximab in a Real-World Setting
    Moots, R. J.
    Xavier, Ricardo
    Mok, Chi Chiu
    Rahman, Mahboob U.
    Tsai, Wen-Chan
    Al Maini, Mustafa
    Pavelka, Karel
    Mahgoub, Ehab
    Kotak, Sameer
    Korth-Bradley, Joan
    Pedersen, Ronald
    Mele, Linda
    Shen, Qi
    Vlahos, Bonnie
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [45] Targeting the Fas/FasL system in Rheumatoid Arthritis therapy: Promising or risky?
    Calmon-Hamaty, Flavia
    Audo, Rachel
    Combe, Bernard
    Morel, Jacques
    Hahne, Michael
    CYTOKINE, 2015, 75 (02) : 228 - 233
  • [46] INCREASE OF PRO-INFLAMMATORY CYTOKINES IS ASSOCIATED WITH ANTI-IDIOTYPE EVENTS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH INFLIXIMAB OR ADALIMUMAB
    Xibille Friedmann, D. X.
    Carrillo Vazquez, S. M.
    Gonzalez Christen, J.
    Vega Morales, D.
    Garza Elizondo, M.
    Hernandez, R.
    Ortiz Panozo, J. E.
    Montiel Hernandez, J. L.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 391 - 392
  • [47] Incidence of Antidrug Antibodies in Rheumatoid Arthritis Patients From Argentina Treated With Adalimumab, Etanercept, or Infliximab in a Real-World Setting
    Maid, Pablo J.
    Xavier, Ricardo
    Real, Rosa M.
    Pedersen, Ron
    Shen, Qi
    Marshall, Lisa
    Solano, Gaston
    Elena Borlenghi, Cecilia
    Pardo Hidalgo, Rodolfo
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 (04) : 177 - 182
  • [48] Effects of Xinfeng capsule on the Fas/FasL-mediated apoptotic pathway in patients with rheumatoid arthritis
    Sun Yue
    Liu Jian
    Cao Yonghe
    JOURNAL OF TRADITIONAL CHINESE MEDICINE, 2018, 38 (04) : 601 - 609
  • [49] Relation of the Fas and FasL gene polymorphisms with susceptibility to and severity of rheumatoid arthritis
    Seyfi Yıldır
    Melek Sezgin
    İbrahim Ömer Barlas
    Gözde Türköz
    Handan Çamdeviren Ankaralı
    Günşah Şahin
    Mehmet Emin Erdal
    Rheumatology International, 2013, 33 : 2637 - 2645
  • [50] Effects of Xinfeng capsule on the Fas/FasL-mediated apoptotic pathway in patients with rheumatoid arthritis
    Sun Yue
    Liu Jian
    Cao Yonghe
    JournalofTraditionalChineseMedicine, 2018, 38 (04) : 601 - 609
12345